We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central ...
Good afternoon, and welcome to Voyager Therapeutics First Quarter 2024 Financial Results Conference Call. [Operator ...
HPP is a rare genetic disease caused by loss of function mutations in the ALPL gene which leads to deficient ALP activity. People living with HPP can experience wide ranging systemic complications ...
The potential translatability of these capsids is supported by data across multiple species, including mice and multiple species of NHP, as well as binding to Alkaline Phosphatase (ALPL ...
Be Biopharma to Present at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
as a potential new treatment for Hypophosphatasia (HPP), a genetic disorder characterized by loss-of-function mutations in the ALPL gene which impairs the mineralization of bones. Researchers used ...
It is said that hiking is the best way to get to know a country. Along the "BergZeitReise" long-distance hiking trail, you can discover the north-easternmost region of Styria step by step in 15 ...
Be Biopharma, Inc. ("Be Bio"), a company pioneering the discovery and development of Engineered B Cell Medicines (BCMs), today presented results from new preclinical research demonstrating production ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback